Cargando…

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

Treatment of hepatitis C virus (HCV) infection has evolved greatly through the recent decade. The availability of direct-acting antiviral agents (DAAs) targeting the functional proteins of HCV has resulted in the introduction of DAA-based combination therapies, providing an optimal rate of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharafi, Heidar, Alavian, Seyed Moayed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177567/ https://www.ncbi.nlm.nih.gov/pubmed/30310532 http://dx.doi.org/10.4254/wjh.v10.i9.543

Ejemplares similares

IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients
por: Sharafi, Heidar, et al.
Publicado: (2011)

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection
por: Rahimi, Pooneh, et al.
Publicado: (2021)

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
por: Rajabi, Abdolhalim, et al.
Publicado: (2021)

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Appropriate Genotyping of Hepatitis B Virus in Iran
por: Jazayeri, Seyed Mohammad, et al.
Publicado: (2015)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Unthought-of Problems Regarding Hepatitis D Virus Infection
por: Alavian, Seyed Moayed
Publicado: (2010)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis
por: Ghaderi-Zefrehi, Hossein, et al.
Publicado: (2016)

New globally faces of hepatitis B and C in the world
por: Alavian, Seyed-Moayed
Publicado: (2011)

An Unbelievable Fact on “Dialysis Centers Without Hepatitis C Infection”
por: Alavian, Seyed Moayed
Publicado: (2014)

Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
por: Moradi, Ghobad, et al.
Publicado: (2021)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

On the Occasion of the World Hepatitis Day: World Hepatitis Day and Our Achievements and Responsibilities in Iran
por: Alavian, Seyed Moayed
Publicado: (2012)

Intravenous Drug Use and Hepatitis C Virus in Iran
por: Zobeiri, Mehdi, et al.
Publicado: (2012)

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals
por: Sharafi, Heidar, et al.
Publicado: (2012)

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
por: Sharafi, Heidar, et al.
Publicado: (2021)

Occult Hepatitis B Virus Infection Among Hemodialysis Patients
por: Alavian, Seyed Moayed
Publicado: (2012)

Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies
por: Rezaee Zavareh, Mohammad Saeid, et al.
Publicado: (2015)

The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C
por: Kadjbaf, Danesh, et al.
Publicado: (2016)

Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

RNA Interference: A Promising Approach for the Treatment of Viral Hepatitis
por: Motavaf, Mahsa, et al.
Publicado: (2012)

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
por: Sharafi, Heidar, et al.
Publicado: (2012)

First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Hasanshahi, Zahra, et al.
Publicado: (2021)

Prevention of Hepatitis A Virus Infection, Need to Vaccinate or Not?
por: Elizee, Pegah Karimi, et al.
Publicado: (2013)

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
por: Dolatimehr, Fardin, et al.
Publicado: (2017)

Tehran Hepatitis Conference: An International Meeting with the Goal of Middle East without Viral Hepatitis
por: Fathi, Meisam, et al.
Publicado: (2016)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

Oral Conditions Might Cause Severe Outcomes in Patients With Viral Hepatitis Infection
por: Mahboobi, Nima, et al.
Publicado: (2014)

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
por: Behnava, Bita, et al.
Publicado: (2016)

Risk factors of hepatitis B infection: Health policy makers should be aware of their importance in each community
por: Miri, Seyed Mohammad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_19dkol92mgt56q9g18b2l5u58d